ArticleBMC immunology2026
Retrospective, single-center analysis of autoimmune hepatitis in Yemeni adults: clinical features, treatment, and outcomes.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune hepatitis (AIH) is a chronic liver disease in which the immune system of the body unintentionally targets liver cells, resulting in inflammation, liver damage, and cirrhosis if treatment is not received. Although the precise origin of AIH remains unknown, experts believe that environmental and genetic factors play significant roles in its pathogenesis. This study describes the clinical, biochemical, and long-term outcomes of patients with autoimmune hepatitis (AIH) at the Science and Technology Hospital in Sana'a, Yemen. METHODOLOGY: This was a retrospective, single-center study.
participantsAll patients with AIH diagnosed at the Science and Technology Hospital between 2019 and 2024 were included.
resultsMost patients were male (18 of 25, 72%). All patients displayed common signs and symptoms of AIH, including hepatomegaly, vomiting, jaundice, and abdominal distention. In addition to positive antinuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA), the majority of individuals showed increased AST levels. The most prevalent hematological abnormalities were thrombocytopenia (64%) and anemia (56%). Regarding the outcome after hospital admission, 60% of cases improved, 12% were discharged against medical advice, 8% died, and 20% had unknown outcomes.
conclusionAutoimmune hepatitis affects patients of Yemeni descent. The most common symptom is jaundice. Only Type I AIH was observed in this cohort, and the mortality rate reached 8%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.